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Abstract: 
Silymarin and, one of its constituents, silibinin exert strong
 
efficacy against prostate cancer (PCA); however, 
anticancer
 
efficacy and associated mechanisms of other components of silymarin,
 
which is a mixture of 
flavonolignans, are largely unknown. Here
 
we have assessed the anticancer efficacy of two pure compounds
 
isosilybin B and isosilybin A, isolated from silymarin, in human
 
prostate carcinoma LNCaP and 22Rv1 cells. 
Isosilybin B and isosilybin
 
A treatment resulted in growth inhibition and cell death together
 
with a strong G1 
arrest and apoptosis in both the cell lines.
 
In the studies examining changes in cell cycle and apoptosis
 
regulators, isosilybin B and isosilybin A resulted in a decrease
 
in the levels of both cyclins (D1, D3, E and A) 
and cyclin-dependent
 
kinases (Cdk2, Cdk4 and cell division cycle 25A), but caused
 
an increase in p21, p27 and 
p53 levels, except in 22Rv1 cells
 
where isosilybin B caused a decrease in p21 protein level. Isosilybin
 
B- and 
isosilybin A-induced apoptosis was accompanied with an
 
increase in the cleavage of poly (ADP-ribose) 
polymerase, caspase-9
 
and caspase-3 and a decrease in survivin levels. Compared with
 
LNCaP and 22Rv1 cells, 
the antiproliferative and cytotoxic potentials
 
of isosilybin B and isosilybin A were of much lesser magnitude
 
in 
non-neoplastic human prostate epithelial PWR-1E cells suggesting
 
the transformation-selective effect of these 
compounds. Together,
 
this study for the first time identified that isosilybin B and
 
isosilybin A, two 
diastereoisomers isolated from silymarin,
 
have anti-PCA activity that is mediated via cell cycle arrest
 
and 
apoptosis induction.
 
 
Abbreviations: PCA, prostate cancer; PI, propidium iodide; CDK, cyclin-dependent kinase; CDKI, cyclin-
dependent kinase inhibitor; Cdc25A, cell division cycle 25A; PARP, poly (ADP-ribose) polymerase 
 
Article: 
Introduction 
Prostate cancer (PCA) is the leading cause of cancer incidences
 
accounting for 33% (234 460) of estimated 
new cases in 2006
 
excluding non-melanoma skin cancers and is the third leading
 
cause of cancer-related deaths 
that accounts for 9% (27 350
 
cases) of all cancer-related deaths in US males (1). Surgical
 
ablation of 
androgens and anti-androgen therapy are two of the
 
therapeutic approaches against locally advanced or 
metastatic
 
PCA (2). Although most patients respond to these therapies initially,
 
the disease ultimately progresses 
to hormone-refractory state
 
(2). Thus, the surgery and current chemotherapeutic options
 
seem to be inadequate 
in controlling and curing PCA, and there
 
is an urgent need for the identification and development of
 
alternative 
strategies. In this regard, prevention and therapeutic
 
intervention by dietary and plant-based drugs have been 
suggested
 
as a newer dimension in the arena of cancer management (3,4).
 
Among various groups of cancer 
chemopreventive agents, extensive
 
experimental data have been generated, which suggest the role
 
of 
polyphenolic flavonoids in chemoprevention of various cancers
 
including PCA (5–8).
 
 
Silymarin is a crude mixture of flavonolignans obtained from
 
the seeds of milk thistle [Silybum marianum (L.) 
Gaertn.]. This
 
group of compounds results from the peroxidase-mediated condensation
 
in the plant between the 
flavonoid, dihydroquercetin and coniferyl
 
alcohol. Silymarin and silibinin (a 50:50 mixture of silybin
 
A and 
silybin B) are widely known for their hepatoprotective
 
activity and has been in clinical use for over three 
decades
 
in Europe and recently in USA and Asia (9). Several studies
 
by others and us in the last decade have 
demonstrated the pre-clinical
 
efficacy of both silymarin and silibinin against various epithelial
 
cancers including 
PCA (10–13), and their efficacy is currently
 
being evaluated in cancer patients (14). This has led us to
 
identify 
and purify specific, biologically active chemical entities
 
present in silymarin with a goal to maximize the 
therapeutic
 
utility of this botanical agent. In this direction, we have
 
isolated, purified and characterized eight 
pure compounds (seven
 
flavonolignans and a flavonoid) from silymarin, namely silybin
 
A, silybin B, isosilybin 
A, isosilybin B, silydianin, silychristin,
 
isosilychristin and taxifolin(10,15). Distinct biological efficacy
 
of these 
compounds was observed in human PCA cells on various
 
cancer end point markers such as cell proliferation, 
prostate-specific
 
antigen secretion and topoisomerase II  promoter activity (10).
 
Isosilybin B and isosilybin A, 
which constitute about 2–4.5%
 
and 5–6.5% of silymarin (w/w), respectively, depending
 
upon the source, were 
effective in most of the parameters studied
 
in both androgen-dependent LNCaP and androgen-independent PC3
 
and DU145 cells (10). For example, the IC50 in DU145 cells for
 
isosilybin B and isosilybin A was 20.5 and 32 
µM, respectively,
 
which was lower compared with silymarin (IC50 67.9 µM)
 
and silibinin (IC50 55.6 µM) (10). 
Though it would be
 
premature to conclude that isosilybin B and isosilybin A were
 
the most effective among all 
the constituents from this one
 
study alone, the data provided us a strong impetus to further
 
examine the efficacy 
and associated mechanisms for isosilybin
 
isomers in PCA cells.
 
 
De-regulated cell cycle and evasion of apoptosis have been recognized
 
as hallmark of cancer progression 
including PCA (16). Cell cycle
 
is known to be regulated by various kinases, namely Cdk4, Cdk2
 
and Cdk1 (or 
cdc2), whose activity is controlled by binding
 
of different cyclins, cyclin-dependent kinase inhibitors (CDKIs)
 
and Cdc25 phosphatases (17,18). Apoptosis refers to programmed
 
cell death in response to various intrinsic or 
extrinsic death
 
signals, and is executed by series of cysteine proteases known
 
as caspases (19,20). Cancer 
chemopreventive agents are known
 
to exert their anticancer effect via modulating the expression
 
of cyclins–
cyclin-dependent kinases (CDKs)–CDKIs
 
and caspases resulting in induction of cell cycle arrest and
 
apoptosis 
(7,8,12,21). Accordingly, in the present study, we
 
investigated the efficacy and mechanism of isosilybin B and
 
isosilybin A in human PCA LNCaP and 22Rv1 cells. For the first
 
time, our findings suggest that both these 
agents impart anti-PCA
 
activity via cell cycle arrest and apoptosis induction involving
 
modulation in cyclins–
CDKs–CDKIs expression and
 
caspase activation together with a decrease in survivin levels.
 
 
Materials and Methods 
Cell lines and reagents 
Isosilybin B and isosilybin A (Figure 1A) were isolated (purity
 
between 98–100%) from silymarin (Madus AG, 
Cologne, Germany)
 
as described previously with modifications to enhance the separation
 
of large-scale amounts 
of each isomer (10,15,22). Human prostate
 
carcinoma LNCaP and 22Rv1 cells and non-neoplastic PWR-1E 
cells
 
were obtained from the American Type Culture Collection (Manassas,
 
VA). RPMI1640, keratinocyte–
SFM media and other cell culture
 
materials were from Invitrogen Corporation (Gaithersberg, MD).
 
Antibody for 
Cip1/p21 was from Upstate (Charlottesville, VA)
 
and for Kip1/p27 and tubulin was from Neomarkers (Fremont, 
CA).
 
Antibodies for Cdk2, Cdk4, cell division cycle 25A (Cdc25A),
 
cyclin D1, cyclin D3, cyclin E and cyclin A 
were from Santa
 
Cruz Biotechnology (Santa Cruz, CA). Hoechst 33342, propidium
 
iodide (PI) and antibody for 
ß-actin were from Sigma–Aldrich
 
Chemical Co. (St Louis, MO). ECL detection system and anti-mouse
 
peroxidase-conjugated secondary antibody were from GE Healthcare
 
(Buckinghamshire, UK). Antibodies for 
cleaved poly (ADP-ribose)
 
polymerase (PARP), cleaved caspase-3, cleaved caspase-9 and
 
anti-rabbit 
peroxidase-conjugated secondary antibody were obtained
 
from Cell Signaling (Beverly, MA). Anti-survivin 
antibody was
 
from Novus Biologicals (Littleton, CO). All other reagents were
 
obtained in their commercially 
available highest purity grade. 
 
 
Fig. 1. Structures of isosilybin A and isosilybin B and the effect of isosilybin B on cell growth and cell death in 
LNCaP, 22Rv1 and PWR-1E cells. (A) The chemical structures of isosilybin A and isosilybin B. (B–D) LNCaP 
cells, 22Rv1 cells or PWR-1E cells were treated with DMSO (control) or various doses of isosilybin B (10–90 
µM) for 24 and 48 h. At the end of each treatment time, both adherent and non-adherent cells were collected 
and processed for determination of total cell number and dead cells as mentioned in Materials and methods. The 
data shown are mean ± standard error of mean of three samples for each treatment. These results were similar in 
three independent experiments. *, P 0.001; #, P 0.01; $, P 0.05. 
Cell culture and treatments 
LNCaP cells (passage 5–45) and 22Rv1 cells (passage 5–30)
 
were cultured in RPMI1640 medium 
supplemented with 10% fetal
 
bovine serum and 100 U/ml penicillin G and 100 µg/ml streptomycin
 
sulfate at 
37°C in a humidified 5% CO2 incubator. PWR-1E
 
cells were cultured in keratinocyte–Serum Free Media 
supplemented
 
with 10% fetal bovine serum, 5 ng/ml human recombinant epidermal
 
growth factor and 0.05 
mg/ml bovine pituitary extract. Cells
 
were plated and treated at 40–50% confluency with different
 
doses of 
isosilybin B and isosilybin A (10–90 µM
 
in medium) dissolved originally in Dimethyl sulfoxide (DMSO)
 
for 
the desired time periods (24–48 h) in serum condition.
 
An equal amount of DMSO (vehicle) was present in each 
treatment,
 
including control; DMSO concentration did not exceed 0.1% (v/v)
 
in any treatment. At the end of 
desired treatments, various
 
analyses were done as described below.
 
 
Cell growth and death assays 
In each case, cells were plated to about 40–50% confluency
 
and treated with isosilybin B and isosilybin A under 
serum condition
 
as detailed above. After 24 and 48 h of treatments, cells were
 
collected by brief trypsinization 
and washed with phosphate-buffered
 
saline. Total cell number was determined by counting each sample
 
in 
duplicate using a hemocytometer under an inverted microscope.
 
Cell viability was determined using trypan blue 
exclusion method.
 
Each treatment and time point had three independent plates.
 
The experiment was repeated 
atleast twice under identical conditions.
 
 
Fluorescence-activated cell sorting analysis for cell cycle distribution 
After identical treatments as detailed above, cells were collected
 
and processed for cell cycle analysis. Briefly, 
0.5 x 105 cells were suspended in 0.5 ml of saponin/PI solution (0.3% saponin (w/v), 25 µg/ml PI (w/v), 0.1 mM 
ethylenediaminetetraacetic
 
acid and 10 µg/ml RNase A (w/v) in phosphate-buffered
 
saline) and incubated 
overnight at 4°C in dark. Cell cycle
 
distribution was then analyzed by flow cytometry using fluorescence-
activated
 
cell sorting analysis core facility of the University of Colorado
 
Cancer Center. The experiment was 
repeated atleast twice under
 
identical conditions.
 
 
Western immunoblotting 
At the end of the desired treatments detailed above, cell lysates
 
were prepared in non-denaturing lysis buffer as 
reported by
 
us (23), and 50–70 µg of protein lysate per sample
 
was denatured in 2x sample buffer and subjected 
to sodium dodecyl
 
sulfate–polyacrylamide gel electrophoresis on 8, 12 or
 
16% Tris–glycine gel. The separated 
proteins were transferred
 
on to nitrocellulose membrane followed by blocking with 5% non-fat
 
milk powder 
(w/v) in Tris-buffered saline (10 mM Tris–HCl,
 
pH 7.5, 100 mM NaCl, 0.1% Tween 20) for 1 h at room 
temperature.
 
Membranes were probed for the protein levels of desired molecules
 
using specific primary 
antibodies followed by peroxidase-conjugated
 
appropriate secondary antibody and visualized by ECL detection
 
system. To ensure equal protein loading, each membrane was stripped
 
and reprobed with anti-ß-actin or anti-
tubulin antibody
 
to normalize for differences in protein loading.
 
 
Apoptosis assay 
Quantitative apoptotic cell death by isosilybin B and isosilybin
 
A in LNCaP and 22Rv1 cells was measured by 
Hoechst assay as
 
described previously (21). Briefly, after desired treatments,
 
cells were collected and then 
stained with DNA-binding dye Hoechst
 
33342 and PI. Apoptotic cells were quantified using fluorescent
 
microscope (Axioskope 2 plus-HBO 100, Zeiss, Jena, Germany)
 
by counting 100 cells per microscopic field (at 
100x magnification) in five fields for each sample in triplicate.  
Statistical analysis 
Statistical analysis was performed using SigmaStat 2.03 software
 
(Jandel Scientific, San Rafael, CA). Data were 
analyzed using
 
t-test and a statistically significant difference was considered
 
to be at P < 0.05. For all the results 
where applicable,
 
the autoradiograms/bands were scanned with Adobe Photoshop 6.0
 
(Adobe Systems, San 
Jose, CA), and the mean density of each
 
band was analyzed by the Scion Image program (National Institutes
 
of 
Health, Bethesda, MD). In each case, blots were subjected
 
to multiple exposures on the film to make sure that 
the band
 
density is in the linear range. Densitometry data presented
 
below the bands are ‘fold change’ as 
compared with
 
control for both isosilybin B and isosilybin A treatments in
 
each case.
 
 
Results 
Pure isosilybin diastereoisomers inhibit growth and induce death of LNCaP and 22Rv1 cells 
We first examined the effect of isosilybin B and isosilybin
 
A on cell growth and cell death in human prostate 
carcinoma
 
LNCaP and 22Rv1 cells. Cells were treated with various doses
 
of these isosilybin isomers and cell 
number and cell death was
 
analyzed by trypan blue exclusion assay. Treatment with isosilybin
 
B (10–90 µM) 
for 24 and 48 h resulted in a decrease
 
in cell number in both LNCaP and 22Rv1 cells in both dose- and
 
time-
dependent manner. In case of LNCaP cells, 24 and 48 h treatments
 
with isosilybin B resulted in 18–35% and 
11–46%
 
decrease in cell number, respectively (Figure 1B). Relatively,
 
a somewhat greater effect was observed 
in 22Rv1 cells where
 
identical isosilybin B treatments for 24 and 48 h exhibited
 
7–50% and 26–66% decreases 
in cell number, respectively
 
(Figure 1C). In LNCaP cells, there was a slight but significant
 
increase in cell death 
after 24 and 48 h of isosilybin B treatment
 
at 60 and 90 µM concentrations (Figure 1B); however, the
 
effect was 
more remarkable in 22Rv1 cells where compared with
 
both 24 and 48 h controls showing 2.7% dead cells, 
isosilybin
 
B treatment for 24 and 48 h at 30–90 µM doses resulted
 
in 7–10% and 10–16% dead cells, 
respectively (Figure 1C).
 
 
Isosilybin A treatment also resulted in a decrease in cell number
 
and an increase in cell death in both LNCaP 
and 22Rv1 cells,
 
and the results obtained here were comparable with those for
 
isosilybin B. In case of LNCaP 
cells, identical isosilybin A
 
treatment for 24 and 48 h resulted in 17–28% and 19–52%
 
decrease in cell number, 
respectively (Figure 2A). In 22Rv1
 
cells, relatively better effect was observed showing 20–42%
 
and 41–62% 
decrease under identical isosilybin A treatments
 
for 24 and 48 h, respectively (Figure 2B). Regarding cell death
 
effect, similar to isosilybin B, isosilybin A treatment resulted
 
in only a slight increase in dead cells in LNCaP 
cells (Figure 2A),
 
whereas the effect in 22Rv1 cells was much more pronounced where
 
the dead cells 
significantly increased to 3–11% and 8–16%
 
of the total number of cells with 30–90 µM doses
 
of isosilybin A 
treatment for 24 and 48 h, respectively, whereas
 
in control, the dead cells were 1.6% after 24 h and 1.8% after
 
48 h (Figure 2B).
 
 
 
Fig. 2. Effect of isosilybin A on cell growth and cell death in LNCaP, 22Rv1 and PWR-1E cells. (A–C) LNCaP 
cells, 22Rv1 cells or PWR-1E cells were treated with DMSO (control) or various doses of isosilybin A (10–90 
µM) for 24 and 48 h. At the end of each treatment time, both adherent and non-adherent cells were collected 
and processed for determination of total cell number and dead cells as mentioned in Materials and methods. The 
data shown are mean ± standard error of mean of three samples for each treatment. These results were similar in 
three independent experiments. *, P 0.001; #, P 0.01; $, P 0.05. 
Lack of isosilybin isomer effects on cell growth in non-neoplastic human prostate epithelial PWR-1E cells 
PWR-1E is an immortalized cell line developed from the non-neoplastic
 
adult human prostatic epithelium using 
adenovirus-12/simian
 
virus-40 (Ad12-SV40) hybrid virus (24). In the studies examining
 
the effect of isosilybin 
B and isosilybin A on PWR-1E cells,
 
neither of the agent showed any significant change in cell growth
 
at 24 h 
and cell viability after 24 and 48 h; however, isosilybin
 
B and isosilybin A treatment at 90 µM dose for 48 h 
decreased
 
the cell number by 25 (Figure 1D) and 9% (Figure 2C) compared
 
with their controls, respectively.
 
 
Isosilybin isomers induce G1 arrest in LNCaP and 22Rv1 cells 
LNCaP and 22Rv1 cells were treated with different doses of isosilybin
 
B and isosilybin A and analyzed for cell 
cycle distribution
 
by fluorescence-activated cell sorting analysis. There was a
 
significant G1 arrest in LNCaP 
cells after 24 h (30, 60 and
 
90 µM) and 48 h (60 and 90 µM) of treatment with
 
isosilybin B, which was 
accompanied by a significant decrease
 
in S phase population (Figure 3A). Further, there was a slight
 
but 
significant increase in G2–M population at 90 µM
 
dose of isosilybin B in LNCaP cells after 48 h of treatment
 
(Figure 3A). In 22Rv1 cells, isosilybin B treatment for 24 and
 
48 h increased the G1 population even at 30 µM 
dose, which
 
increased further in a dose-dependent manner (Figure 3A). This
 
increase in G1 population at both 
the time points was at the
 
expense of S and G2/M phase cells which decreased in a dose-dependent
 
manner. 
Similarly, isosilybin A treatment also resulted in an
 
increase in G1 population after 24 h (10, 30, 60 and 90 µM)
 
and 48 h (90 µM) of treatment in LNCaP cells (Figure 3B).
 
Further, there was a slight increase in the G2–M 
population
 
after 48 h of treatment. In 22Rv1 cells, the treatment of isosilybin
 
A increased the G1 population after 
24 and 48 h, which was accompanied
 
by a significant decrease in S phase population (Figure 3B).
 
 
 
Fig. 3. Effect of isosilybin B and isosilybin A on cell cycle distribution in human PCA LNCaP and 22Rv1 cells. 
LNCaP or 22Rv1 cells were treated with DMSO or various doses (10–90 µM) of isosilybin B and isosilybin A 
for 24 and 48 h. At the end of each treatment, cells were collected and incubated overnight with saponin/PI 
solution at 4°C and subjected to fluorescence-activated cell sorting analysis as detailed in Materials and 
methods. (A) Quantitative cell cycle distribution data for isosilybin B in LNCaP and 22Rv1 cells after 24 and 
48 h of treatment. (B) Quantitative cell cycle distribution data for isosilybin A in LNCaP and 22Rv1 cells after 
24 and 48 h of treatment. The data shown are mean ± standard error of mean of three samples for each 
treatment. These results were similar in two independent experiments. *, P 0.001; #, P 0.01; $, P 0.05 
Isosilybin isomers modulate expression of G1 phase cell cycle regulators 
We observed a strong G1 arrest with isosilybin B and isosilybin
 
A in LNCaP and 22Rv1 cells after 24 and 48 h 
of treatment; therefore,
 
we next examined the effect of these compounds on the levels
 
of cyclins (D1, D3, E and 
A), CDKs (Cdk2 and Cdk4), CDKIs (p27
 
and p21) and Cdc25A, which are known to regulate the G1 phase
 
of 
cell cycle (17,18). Isosilybin B treatment (10–90 µM)
 
of LNCaP cells resulted in a moderate to strong decrease 
in
 
the levels of cyclins D3, D1, A and E along with a decrease
 
in the level of Cdk4, Cdk2 and Cdc25A (Figure 
4). Isosilybin
 
B treatment, however, increased the levels of p27 and p21 in
 
LNCaP cells (Figure 4). In 22Rv1 
cells also, treatment of isosilybin
 
B (60 and 90 µM doses) for 24 and 48 h resulted in a decrease
 
in the levels of 
cyclins D3, D1, E and A along with a decrease
 
in the levels of Cdk2, Cdk4 and Cdc25A in a dose- and time-
dependent
 
manner (Figure 5). Isosilybin B treatment also resulted in a
 
slight to moderate increase in the levels 
of p27, whereas the
 
levels of p21 decreased under similar treatment conditions (Figure 5).
 
Similar to isosilybin 
B, isosilybin A treatment resulted in
 
a decrease in the levels of cyclins D3, D1, E and A along with
 
decrease in 
the levels Cdk2 and Cdk4 in LNCaP cells (Figure 4).
 
In 22Rv1 cells, isosilybin A treatment caused only a slight
 
to moderate decrease in the levels of cyclins D3, E, A and Cdk2
 
(Figure 4). Isosilybin A treatment also 
increased the levels
 
of p21 and p27 in both LNCaP and 22Rv1 cells (Figures 4 and
 
5). Further, there was a 
decrease in the level of Cdc25A in
 
both the cell lines with isosilybin A treatment (Figures 4 and
 
5). Membranes 
were stripped and reprobed with anti-ß-actin
 
antibody for protein loading correction. 
 
 
Fig. 4. Effect of isosilybin B and isosilybin A on G1 cell cycle regulatory molecules in LNCaP cells. LNCaP 
cells were treated with DMSO or various doses of isosilybin B and isosilybin A (10, 30, 60 and 90 µM) for 24 
and 48 h. At the end of each treatment time, cell lysates were prepared in non-denaturing lysis buffer as 
mentioned in Materials and methods. For each sample, 50–60 µg of protein lysate was used for sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis and western immunoblotting, and membranes were probed for 
cyclin D3, cyclin D1, Cdk4, Cdk2, cyclin E, cyclin A, Cdc25A, p21, p27 and p53. Membranes were also 
stripped and reprobed with anti-ß-actin antibody for protein loading correction. Blots shown are representative 
of atleast two independent experiments in each case out of the experiments done at different cell passage 
number. The densitometry data presented below the bands are ‘fold change’ as compared with control after 
normalization with respective loading control (ß-actin). 
 
 
Fig. 5. Effect of isosilybin B and isosilybin A on G1 phase cell cycle regulatory molecules in 22Rv1 cells. 
22Rv1 cells were treated with DMSO or various doses of isosilybin B and isosilybin A (60 and 90 µM) for 24 
and 48 h. At the end of each treatment time, cell lysates were prepared in non-denaturing lysis buffer as 
mentioned in Materials and methods. For each sample, 50–60 µg of protein lysate was used for sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis and western immunoblotting, and membranes were probed for 
cyclin D3, cyclin D1, Cdk4, Cdk2, cyclin E, cyclin A, Cdc25A, p21, p27 and p53. Membranes were also 
stripped and reprobed with anti-ß-actin antibody for protein loading correction. Blots shown are representative 
of atleast two independent experiments in each case out of the experiments done at different cell passage 
number. The densitometry data presented below the bands are ‘fold change’ as compared with control after 
normalization with respective loading control (ß-actin). 
Isosilybin B and isosilybin A treatment increases p53 level 
P53 is known as a tumor suppressor gene important for the maintenance
 
of genome integrity. In response to 
stress signal, the p53 protein
 
is accumulated in a specific manner by post-translational modifications
 
leading to 
either cell cycle arrest or apoptosis (25). Since
 
we observed an induction of cell cycle arrest and apoptosis
 
with 
isosilybin B and isosilybin A treatment in LNCaP and 22Rv1
 
cells both of which harbor wild-type p53, we also 
examined the
 
effect of these compounds on p53 level. Both isosilybin B and
 
isosilybin A treatment increased the 
total p53 levels in LNCaP
 
and 22Rv1, which was more prominent after 48 h of treatment
 
(Figures 4 and 5).
 
 
Isosilybin isomers induce apoptotic death in LNCaP and 22Rv1 cells 
Since we observed cell death with these agents together with
 
a strong G1 arrest that might lead the cell to 
apoptotic exit
 
from the cell cycle, we next examined the effect of these compounds
 
on the apoptotic death of 
LNCaP and 22Rv1 cells after 48 h of
 
treatment. As shown in Figure 6A, apoptotic population increased
 
significantly by 2-folds with 90 µM isosilybin B in LNCaP
 
cells as measured by Hoechst staining. The increase 
was about
 
2- to 3-fold with 60 and 90 µM dose of isosilybin A after
 
48 h of treatment in LNCaP cells. In 22Rv1 
cells, treatment
 
of 60 and 90 µM dose of isosilybin B for 48 h resulted
 
in an increase in apoptotic cell population 
by 3- to 4-fold,
 
whereas with isosilybin A, apoptotic cell population increased
 
by about 4- to 5-fold at identical 
doses (Figure 6A).
 
 
 
 
 
Fig. 6. Isosilybin B and isosilybin A induce apoptosis in human prostate carcinoma LNCaP and 22Rv1 cells. 
(A) LNCaP and 22Rv1 cells were treated with DMSO or 60 and 90 µM doses of isosilybin B and isosilybin A 
for 48 h. Both adherent and non-adherent cells were collected and stained with Hoechst and apoptotic cell 
population was measured as mentioned in Materials and methods. Data shown are mean ± standard error of 
mean of three samples for each treatment. These results were similar in two independent experiments. *, P 
0.001; #, P 0.01, NS, non-significant. (B) LNCaP cells were treated with DMSO or various doses of isosilybin 
B and isosilybin A (10, 30, 60 and 90 µM) for 48 h. At the end of each treatment time, cell lysates were 
prepared in non-denaturing lysis buffer as mentioned in Materials and methods. For each sample, 60–70 µg of 
protein lysate was used for sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western 
immunoblotting, and membranes were probed for cleaved PARP, cleaved caspase-3, cleaved caspase-9 and 
survivin. Membranes were also stripped and reprobed with anti-tubulin antibody for protein loading correction. 
(C) 22Rv1 cells were treated with DMSO or 60 and 90 µM doses of isosilybin B and isosilybin A for 24 and 48 
h. At the end of each treatment time, western blot analysis was performed for cleaved PARP, cleaved caspase-3, 
cleaved caspase-9 and survivin. Membranes were also stripped and reprobed with anti-tubulin antibody for 
protein loading correction. Blots shown are representative of two independent experiments in each case. The 
densitometry data presented below the bands are ‘fold change’ as compared with control after normalization 
with respective loading control (tubulin). 
 
Isosilybin isomers-induced apoptosis involves caspase-3, caspase-9 and PARP cleavage and a decrease in 
survivin level 
We observed a significant increase in apoptotic population by
 
both isosilybin compounds; therefore, we next 
examined their
 
effect on the molecules that are known to regulate and execute
 
apoptosis. Treatment of LNCaP 
and 22Rv1 cells with isosilybin
 
B and isosilybin A resulted in a dose-dependent increase in
 
the PARP cleavage 
(Figure 6B and C), which is a known marker
 
for apoptosis (26). Since caspases are known as executers of
 
apoptosis (19,27), we also examined the effect of isosilybin
 
B and isosilybin A on the levels of cleaved caspase-
9 and cleaved
 
caspase-3. As shown in Figure 6B, there was a slight increase
 
in the levels of these active 
fragments in LNCaP cells after
 
48 h of treatment with these agents; however, in 22Rv1 cells,
 
similar treatments 
resulted in a much more prevalent increase
 
in the levels of cleaved caspase-3 and cleaved caspase-9 (Figure 
6C).
 
 
Survivin belongs to the family of inhibitor of apoptosis proteins
 
and is generally over-expressed in cancer cells 
(28). Since
 
it is known to counter apoptosis by inhibiting the activation
 
of caspases (29,30), we next examined 
the effect of isosilybin
 
B and isosilybin A on the survivin level in LNCaP and 22Rv1
 
cells, and found that there 
was a slight to moderate decrease
 
with both agents in both the cell lines (Figure 6B and C).
 
 
Discussion 
Pure preparations have only become available recently of the
 
milk thistle flavonolignan diastereoisomers, 
isosilybin A and
 
isosilybin B. Isosilybin A and isosilybin B share the same chemical
 
formula and structure with 
the exception of the stereochemical
 
positions of the terminal aryl (3-methoxy-4-hydroxyphenyl) and
 
hydroxymethyl groups at the and ß carbons (Figure 1A).
 
Further, both possess the same 1' linkage between 
flavonoid
 
and lignan moiety, which has been earlier suggested to be responsible
 
for the overall growth 
inhibitory action of flavonolignans isolated
 
and purified from silymarin (10). The findings of the present
 
study 
suggest that isosilybin B and isosilybin A exert strong
 
antiproliferative effects against human prostate 
carcinoma LNCaP
 
and 22Rv1 cells and that this effect involves alterations in
 
cell cycle regulators, causing both 
G1 arrest as well as induction
 
of cell death via apoptosis. Importantly, we found that these
 
two compounds 
exhibited very little to moderate antiproliferative
 
effect in immortalized non-neoplastic human prostate 
epithelial
 
PWR-1E cells depending upon the duration of treatment, suggesting
 
that these compounds exhibit 
cytotoxicity selectively against
 
cancer cells. Furthermore, this is the first detailed comparative
 
mechanistic study 
for the diastereoisomers isosilybin B and
 
isosilybin A for their apoptotic and cell cycle effects in human
 
PCA 
cells.
 
 
Progression through the various phases of cell cycle is mediated
 
by CDKs in complex with specific cyclins (31). 
Cyclin D1 and
 
cyclin D3 are known to form complex with Cdk4, whereas cyclin
 
E and cyclin A bind to and 
activate Cdk2. These activated kinases
 
then phosphorylate Rb protein to release E2F transcription factors
 
to 
transcribe genes needed for the G1 to S transition (31).
 
Molecular analyses of human cancers have revealed that 
cell
 
cycle is abnormally regulated by aberrant expression of key
 
cyclins and CDKs (32–35). For example, cyclin 
E is over-expressed
 
in human breast, gastric, colorectal, leukemia, genitourinary
 
tract, lung and skin cancers 
(32), and cyclin D1 is also over-expressed
 
in many cancers, including PCA (33). In the present study, both
 
agents resulted in a decrease in cyclin D1, D3, E and A levels
 
along with a decrease in Cdk4 and Cdk2 protein 
levels, which
 
might have a direct relevance to the observed G1 arrest in both
 
LNCaP and 22Rv1 cells by these 
agents.
 
 
The Cip/Kip CDKI family represents another group of cell cycle
 
regulators, which are known to regulate G1–S 
and G2–M
 
phase transitions (17). p21 (Cip1) is known to interact with
 
cyclin D–Cdk4 complex and p27 (Kip1) 
suppresses the activity
 
of cyclin E–Cdk2 complex (17). The loss of p21 and p27
 
expression has been found to be 
associated with a poor prognosis
 
in a number of different human tumors including laryngeal, breast,
 
gastric, 
non-small-cell lung and prostate carcinomas (36). Our
 
results showed that both isosilybin B and isosilybin A 
increase
 
Cip1/p21 and Kip1/p27 protein levels except in 22Rv1 cells,
 
where isosilybin B treatment resulted in a 
decrease in the levels
 
of p21. Further studies are needed to examine the role of isosilybin
 
B-mediated decrease 
in p21.
 
 
Cdc25A belongs to dual specificity phosphatase family and controls
 
cell cycle progression by 
dephosphorylating and activating CDKs
 
at positions Thr14 and Tyr15 (18). Cdc25A has been described
 
as an 
oncogene and is over-expressed in a wide variety of tumors
 
(37). Microinjection of antibodies against Cdc25A 
arrests cells
 
before S phase (38). Isosilybin A and isosilybin B treatment
 
resulted in a decrease in the levels of 
Cdc25A, which might
 
have a potential role in inactivation of CDK and thus contributing
 
to the observed G1 
arrest.
 
 
Several lines of evidence indicate that progression of the cell
 
cycle and control of apoptosis are intimately 
linked processes,
 
even though both have separate regulatory molecular mechanisms
 
(39,40). The G1 phase arrest 
of cell cycle progression provides
 
an opportunity for cells to either undergo repair mechanisms
 
or follow the 
apoptotic pathway. Our results showed that both
 
isosilybin isomers induce apoptosis in LNCaP and 22Rv1 cells.
 
Apoptosis is known to be tightly regulated by pro-apoptotic
 
and anti-apoptotic effector molecules and can be 
mediated by
 
several different pathways in response to various intrinsic
 
and extrinsic signals (20,41). These 
signals affect the membrane
 
potential of mitochondria and resulting in release of cytochrome
 
c, which binds 
with Apaf-1, resulting in activation of caspase-9
 
and subsequently caspase-3 (21,42). The activation of caspase-
3
 
leads to the cleavage and inactivation of key cellular proteins,
 
such as PARP, resulting in disassembly of the 
cell (27). We
 
found that isosilybin B and isosilybin A increased the cleavage
 
of caspase-9 and caspase-3 
followed by PARP cleavage. These
 
results suggest the potential role of caspases activation by
 
both the 
compounds in both LNCaP and 22Rv1 cells.
 
 
Activation of caspases is regulated by various proteins, including
 
the inhibitory proteins of the inhibitor of 
apoptosis protein
 
family (43). Survivin belongs to inhibitor of apoptosis protein
 
family and is over-expressed in 
vast majority of cancers including
 
esophageal, lung, ovarian, breast, colorectal, bladder, gastric,
 
prostate, 
pancreatic, laryngeal, uterine etc. (28). Survivin
 
is known to act as death suppressor as a result of caspase 
inhibition
 
(29,30). Additionally, survivin has been shown to interact directly
 
with Cdk4 and plays a role in 
Cdk2/cyclin E activation resulting
 
in G1 transition (44). Isosilybin B and isosilybin A treatment
 
resulted in a 
decrease in the levels of survivin, which might
 
contribute to both cell cycle arrest and induction of apoptosis
 
as 
observed in LNCaP and 22Rv1 cells.
 
 
As mentioned earlier, p53 is a tumor suppressor gene and is
 
activated in response to various intrinsic and 
extrinsic stress
 
signals (25). Activated p53 is a sequence specific DNA-binding
 
transcriptional factor and some 
of the target genes of its transcriptional
 
activity are important for cell cycle arrest or for inducing
 
apoptosis (45). 
For example, p53 regulated genes (Apaf-1, bax,
 
noxa, puma etc.) are known to initiate a protein cascade leading
 
to the activation of caspase-9 and then caspase-3 followed by
 
apoptosis (45,46). Similarly, role of p53 in cell 
cycle arrest
 
has been shown via regulating the expression of p21, cdc25A
 
and 14-3-3 sigma (37,45,46). In the 
present work, we observed
 
an increase in the level of p53 with isosilybin B and isosilybin
 
A treatment, which 
might contribute to the observed cell cycle
 
arrest and apoptosis; however, more studies are needed in future
 
to 
establish such a cause and effect relationship.
 
 
In conclusion, the results of the present study indicate that
 
isosilybin B and isosilybin A inhibit proliferation and 
induce
 
G1 phase arrest and apoptosis in human PCA cells. Isosilybin
 
B was more effective in its effect on 
reducing cyclin D1 and
 
cyclin D3 levels compared with isosilybin A in LNCaP cells.
 
Similarly, in 22Rv1 cells, 
isosilybin B was more effective in
 
down-regulating the levels of cyclins (D1, D3, E and A) and
 
CDKs (Cdk4 
and Cdk2) and Cdc25A, whereas isosilybin A was more
 
effective in the induction of CDKIs (p21 and p27). 
These results
 
point toward a difference in the mechanism for induction of
 
G1 phase arrest by isosilybin B and 
isosilybin A. Similarly,
 
we found higher apoptotic cell population with isosilybin A
 
compared with isosilybin B 
in both LNCaP and 22Rv1 cells suggesting
 
that isosilybin A might be more potent in its apoptotic action.
 
In 
non-tumorigenic PWR-1E cells where both compounds had minimal
 
effects, isosilybin A showed lesser potency 
compared with isosilybin
 
B in inhibiting cell proliferation. These results suggest that
 
these two diastereoisomers 
do have distinct cellular targets,
 
which might be due to the difference in the positioning of functional
 
groups in 
their lignan moieties (Figure 1A). However, further
 
studies are needed in future to address these issues as both
 
compounds also have many overlapping effects as summarized in
 
Table 1. Overall, this study provided the first 
detailed account
 
of anticancer efficacy of isosilybin B and isosilybin A against
 
human prostate carcinoma cells.
 
 
Table I. Summary of the results of isosilybin B and isosilybin A in LNCaP and 22Rv1 cells  
Molecules studied Isosilybin B Isosilybin A Significance 
 LNCaP 22Rv1 LNCaP 22Rv1  
 
Cyclin D3     Cell cycle arrest 
Cyclin D1    — Cell cycle arrest 
Cdk4    — Cell cycle arrest 
Cdk2     Cell cycle arrest 
Cyclin E     Cell cycle arrest 
Cyclin A     Cell cycle arrest 
Cdc25A     Cell cycle arrest 
p21     Cell cycle arrest 
p27     Cell cycle arrest 
Cleaved PARP     Apoptosis 
Cleaved caspase-3     Apoptosis 
Cleaved caspase-9     Apoptosis 
Survivin     Cell cycle arrest, apoptosis 
p53     Cell cycle arrest, apoptosis 
 
Increases with isosilybin B or isosilybin A treatment.  
Decreases with isosilybin B or isosilybin A treatment.  
— No change with isosilybin B or isosilybin A treatment. 
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